《Cancer Communications》雜志的最新年發文量為46篇。
這表明該刊在每年都會精選并發表一定數量的高質量文章，以保持其在腫瘤學領域的學術影響力。
該刊聚焦于醫學-腫瘤學領域的前沿研究，致力于推動該領域新技術和新知識的傳播與應用。同時它積極鼓勵研究人員詳細發表其高質量的實驗研究和理論成果。
該刊的平均審稿周期約為 4 Weeks 。
Cancer Communications 雜志發文統計
文章名稱引用次數
- Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?224
- The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer68
- Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer57
- Lipid metabolism reprogramming and its potential targets in cancer42
- Boron delivery agents for neutron capture therapy of cancer40
- When fats commit crimes: fatty acid metabolism, cancer stemness and therapeutic resistance31
- A realistic appraisal of boron neutron capture therapy as a cancer treatment modality30
- Mucinous colorectal adenocarcinoma: clinical pathology and treatment options25
- Precision medicine becomes reality-tumor type-agnostic therapy24
- Protein-coding genes combined with long noncoding RNA as a novel transcriptome molecular staging model to predict the survival of patients with esophageal squamous cell carcinoma21
國家/地區發文量
- CHINA MAINLAND191
- USA34
- Singapore7
- England5
- GERMANY (FED REP GER)5
- Italy5
- Japan5
- South Korea4
- Taiwan3
- Canada2
